Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Lymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), central nerve cell lymphoma, and follicular lymphoma. The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Mini reviews in medicinal chemistry - (2023) vom: 15. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Shuxian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B-cell lymphoma? |
|---|
| Anmerkungen: |
Date Revised 19.09.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/1389557523666230915103121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36221509X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36221509X | ||
| 003 | DE-627 | ||
| 005 | 20231226090756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389557523666230915103121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM36221509X | ||
| 035 | |a (NLM)37724679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Shuxian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Advances in Nanobiotechnology for the Treatment of Non-Hodgkin's Lymphoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Lymphoma is the eighth most common type of cancer worldwide. Currently, lymphoma is mainly classified into two main groups: Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL), with NHL accounting for 80% to 90% of the cases. NHL is primarily divided into B, T, and natural killer (NK) cell lymphoma. Nanotechnology is developing rapidly and has made significant contributions to the field of medicine. This review summarizes the advancements of nanobiotechnology in recent years and its applications in the treatment of NHL, especially in diffuse large B cell lymphoma (DLBCL), central nerve cell lymphoma, and follicular lymphoma. The technologies discussed include clinical imaging, targeted drug delivery, photodynamic therapy (PDT), and thermodynamic therapy for lymphoma. This review aims to provide a better understanding of the use of nanotechnology in the treatment of non-Hodgkin's lymphoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B-cell lymphoma? | |
| 650 | 4 | |a Diagnosis ? | |
| 650 | 4 | |a Nanobiotechnology? | |
| 650 | 4 | |a Nanomaterials | |
| 650 | 4 | |a Non-Hodgkin's lymphoma | |
| 650 | 4 | |a combination therapy? | |
| 700 | 1 | |a Xu, Minghao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Xiangmin |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Suying |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mini reviews in medicinal chemistry |d 2001 |g (2023) vom: 15. Sept. |w (DE-627)NLM121595404 |x 1875-5607 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:15 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1389557523666230915103121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 15 |c 09 | ||